hVIVO PLC (AIM:HVO) chief executive Yamin ‘Mo’ Khan talked with Proactive's Stephen Gunnion about the company’s trading update for the first half of 2025 and shared insights into its outlook and operational progress.
hVIVO reported first-half revenue of £24 million, with Khan highlighting growth from diversified services, particularly in laboratory operations under hLab and through the newly acquired Clinical Research Services (CRS). EBITDA margins stood at around 12%, aided by operational efficiencies and upfront non-refundable fees from cancelled contracts. The company remains debt-free with cash deposits of approximately £23 million.
Discussing acquisitions, Khan noted that integration of CRS and Cryostore is progressing well. CRS has contributed £5.2 million in revenue, while Cryostore added £300,000. Integration efforts have aligned teams and backend operations, though system integration is ongoing.
While macroeconomic headwinds have delayed clinical trial decisions—driven by US regulatory shifts and biotech funding pressures—Khan said the order book stood at £40 million at June-end, and proposals submitted this year already exceed those of 2024. “Our sales pipeline is strong… I expect our proposal submitted this year to be significantly higher than in 2024,” he said.
Looking ahead, hVIVO aims for £47 million in revenue for 2025. The company is diversifying beyond infectious diseases, tapping into areas like cardio-metabolic trials, positioning itself for broader growth.
For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future content.
#hVIVO #ClinicalTrials #BiotechNews #LifeSciences #PharmaUpdates #CRS #Cryostore #RevenueGrowth #EBITDA #DrugDevelopment #Cardiometabolic #HumanChallengeTrials #LabServices #UKBiotech
